MedPath

Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix

Not Applicable
Terminated
Conditions
Foot Ulcer, Diabetic
Interventions
Other: Standard of Care Moist Wound Therapy
Device: PriMatrix Moist Wound Therapy
Registration Number
NCT01729286
Lead Sponsor
Integra LifeSciences Corporation
Brief Summary

The objective of this study is to compare the effectiveness of PriMatrix Moist Wound Therapy (MWT) with Standard of Care MWT for the treatment of chronic diabetic foot ulcers in subjects with diabetes mellitus and without significantly compromised arterial circulation.

Detailed Description

This study will be a multi-center, prospective, randomized single-blinded study evaluating the efficacy of PriMatrix MWT versus Standard of Care MWT in achieving complete wound closure of chronic diabetic foot ulcers by 12 weeks (84 days). To measure wound recidivism and changes in functional quality of life, each subject will complete the Cardiff Wound Impact Schedule and the SF-36v2™ at three time points during the study i) at initial screening, ii) at completion of treatment phase, and iii)at 24 weeks (post-randomization). Additionally, the data obtained from the SF-36v2™ will be used in an economic evaluation of the treatment arms.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
92
Inclusion Criteria
  • Type I or Type II diabetes
  • A diabetic foot ulcer located on the foot or ankle at least one square centimeter
Exclusion Criteria
  • Suspected or confirmed signs/symptoms of wound infection
  • Hypersensitivity to bovine collagen

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard of Care Moist Wound TherapyStandard of Care Moist Wound Therapysharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
PriMatrix Moist Wound TherapyStandard of Care Moist Wound Therapysharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
PriMatrix Moist Wound TherapyPriMatrix Moist Wound Therapysharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
Primary Outcome Measures
NameTimeMethod
Complete wound closureby 12 weeks
Secondary Outcome Measures
NameTimeMethod
Change in quality of life measurements between PriMatrix and Standard of Carebetween baseline and 24 weeks
Change in predicted medical expenditures between PriMatrix and Standard of Careover 24 weeks
Nonserious and serious adverse eventsover 24 weeks

Trial Locations

Locations (18)

University of Southern California

🇺🇸

Los Angeles, California, United States

Foot and Ankle Clinic

🇺🇸

Los Angeles, California, United States

Advanced Research Institute of Miami

🇺🇸

Miami, Florida, United States

Joseph M. Still Research Foundation

🇺🇸

Augusta, Georgia, United States

American Health Network

🇺🇸

Carmel, Indiana, United States

Advanced Foot & Ankle Specialists

🇺🇸

Tampa, Florida, United States

Foot & Andle Center of Mooresville

🇺🇸

Mooresville, Indiana, United States

Imperial Health

🇺🇸

Lake Charles, Louisiana, United States

Kansas City Vascular

🇺🇸

North Kansas City, Missouri, United States

Wake Forest University

🇺🇸

Winston-Salem, North Carolina, United States

Fairfield Medical Center

🇺🇸

Lancaster, Ohio, United States

St. Anthony's Medical Center

🇺🇸

St. Louis, Missouri, United States

North Shore Long Island Jewish Comprehensive Wound Healing Center

🇺🇸

Lake Success, New York, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Centro Podiatrico del Norte

🇵🇷

Arecibo, Puerto Rico

Renier Gonzalez-Cruz

🇵🇷

Juana Diaz, Puerto Rico

VA Carribean Healthcare System

🇵🇷

San Juan, Puerto Rico

University of Tennessee

🇺🇸

Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath